Trials / Not Yet Recruiting
Not Yet RecruitingNCT06948539
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
A Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2101 for Injection in Subjects With Advanced Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2101 for injection | TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate. |
Timeline
- Start date
- 2025-04-01
- Primary completion
- 2026-10-01
- Completion
- 2026-12-01
- First posted
- 2025-04-29
- Last updated
- 2025-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06948539. Inclusion in this directory is not an endorsement.